Sign In
Buy VKTX
$32.37
+1.99 (+6.55%)
At Close: Jun 22, 2026
Why Viking Therapeutics, 67% Off Its Recent Highs, Could Still Have An Edge In Obesity
02:07pm, Wednesday, 25'th Jun 2025
Viking Therapeutics stock remains under pressure, but analysts said Wednesday the company's strategy for its Phase 3 studies could pay off.
What's Going On With Viking Therapeutics Stock On Wednesday?
01:01pm, Wednesday, 25'th Jun 2025
Viking Therapeutics, Inc. VKTX on Wednesday initiated the VANQUISH Phase 3 clinical program for VK2735, the company's dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulino
Viking Therapeutics Announces Initiation of Phase 3 Obesity Clinical Program with GLP-1/GIP Agonist VK2735
07:03am, Wednesday, 25'th Jun 2025
VANQUISH-1 and VANQUISH-2 Studies to Evaluate Subcutaneous VK2735 in Obese Adults with and without Type 2 Diabetes SAN DIEGO , June 25, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ:
My 5 Favorite Dirt Cheap Stocks to Buy Right Now
07:10am, Tuesday, 24'th Jun 2025
Though indexes have rebounded, the first half of the year has been rocky for investors. The market had to digest a variety of uncertainties, from geopolitical problems to mixed economic data and the U
Pharma companies need to beef up M&A right now, says Mizuho's Jared Holz
06:10pm, Monday, 23'rd Jun 2025
Jared Holxz, Mizuho, joins 'Fast Money' to talk competition in the obesity drug space.
2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts
06:10pm, Saturday, 21'st Jun 2025
If you're looking to add growth to your portfolio, biotech stocks can be a great choice. Exciting research is happening in these companies' labs, and in some cases, game-changing treatment candidates
Missed Out on Eli Lilly's 480% Gains Over the Past 5 Years? These GLP-1 Stocks Still Have Plenty of Upside.
09:53am, Wednesday, 18'th Jun 2025
Eli Lilly (LLY -0.41%) has been one of the hottest healthcare stocks to own in recent years, thanks in large part to the success of its incredibly successful GLP-1 agonist drugs, which help patients w
Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a Bet
10:31am, Monday, 16'th Jun 2025
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employe
Viking Therapeutics, Inc. (VKTX) Stock Drops Despite Market Gains: Important Facts to Note
06:46pm, Thursday, 12'th Jun 2025
The latest trading day saw Viking Therapeutics, Inc. (VKTX) settling at $28.59, representing a -1.26% change from its previous close.
1 Stock Down 34% This Year to Buy and Hold
05:55am, Sunday, 08'th Jun 2025
Shares of Viking Therapeutics (VKTX 2.88%), a mid-cap biotech, are down by 34% this year. This poor performance may suggest that recent company-specific developments have rendered the stock less attra
Altimmune Vs. Viking Therapeutics: Evaluating Pipeline Maturity, And Takeover Potential
10:51am, Monday, 02'nd Jun 2025
I rate Altimmune a 'Strong Buy' and Viking Therapeutics a 'Buy' for high-risk, long-term investors. ALT's Pemvidutide stands out for its lean mass protection, visceral fat reduction, and potential in
3 Best Growth Stocks to Buy in June
06:15am, Monday, 02'nd Jun 2025
Growth investors have had to work harder than usual to find winners in 2025. With the S&P 500 essentially flat year to date amid President Trump's global trade reset and persistent inflation concerns,
Is It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views?
10:36am, Friday, 30'th May 2025
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analy
Novo Nordisk vs. Viking Therapeutics: Which GLP-1 Stock Has More Upside?
01:41pm, Tuesday, 27'th May 2025
With VKTX surging on clinical results and NVO investing to cement market share, investors face a high-stake GLP-1 showdown.
Viking Therapeutics: Buy It For The Future And Ignore The Noise
09:00am, Tuesday, 27'th May 2025
VKTX remains a speculative, high-risk/reward play, with its future hinging on successful Phase III trial results for its obesity drug pipeline. The company's strong cash position and recent manufactur
